0 (0%)		09-27 09:34
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	59.66	1-year :	69.68
Resists	First :	51.08	Second :	59.66
Pivot price	50.97
Supports	First :	50.92	Second :	50.83
MAs	MA(5) :	51.03	MA(20) :	50.95
	MA(100) :	50.93	MA(250) :	50.92
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	97.9	D(3) :	98.6
RSI	RSI(14): 67.2
52-week	High :	51.34	Low :	49.75

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FLOT ] has closed below upper band by 0.7%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	51.14 - 51.34	51.34 - 51.52
Low:	50.47 - 50.72	50.72 - 50.94
Close:	50.64 - 51.06	51.06 - 51.41

Tue, 16 Sep 2025
FLOT Reduces CLDN18.2 in Gastric Cancer, Raising Questions About Targeting - Oncology News Central

Tue, 22 Jul 2025
Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy - Wiley Online Library

Thu, 03 Jul 2025
Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer - Targeted Oncology

Thu, 05 Jun 2025
Durvalumab Plus FLOT Improves Early Upper-GI Cancer - Medscape

Sun, 01 Jun 2025
New Hope for People With Stomach and Esophagus Cancer: Using Immunotherapy To Help Prevent the Disease From Coming Back - Memorial Sloan Kettering Cancer Center

Sun, 01 Jun 2025
MATTERHORN: Durvalumab + Chemotherapy Demonstrates Superior EFS Over Standard of Care in Resectable Gastric/GEJ Cancer - ASCO Daily News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.